# A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors

> **NCT05086848** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Irinotecan liposome、5-fluorouracil、Leucovorin

## Key facts

- **NCT ID:** NCT05086848
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-05
- **Primary completion:** 2018-06-06
- **Final completion:** 2018-06-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05086848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05086848, "A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05086848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*